Ovid CEO Has High Hopes for OV101 to Treat Angelman Worldwide
Pharmaceutical industry leader Jeremy Levin believes his company is on the cusp of winning approval for the first medicine that treats the underlying cause of Angelman syndrome. Levin is CEO of New York-based Ovid Therapeutics, a publicly traded company that’s poured a good chunk of its resources into…